KR101929074B1 - 프티로스틸벤의 항불안 효과 - Google Patents

프티로스틸벤의 항불안 효과 Download PDF

Info

Publication number
KR101929074B1
KR101929074B1 KR1020137032950A KR20137032950A KR101929074B1 KR 101929074 B1 KR101929074 B1 KR 101929074B1 KR 1020137032950 A KR1020137032950 A KR 1020137032950A KR 20137032950 A KR20137032950 A KR 20137032950A KR 101929074 B1 KR101929074 B1 KR 101929074B1
Authority
KR
South Korea
Prior art keywords
anxiety
composition
rti
doses
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137032950A
Other languages
English (en)
Korean (ko)
Other versions
KR20140107112A (ko
Inventor
아그네스 엠. 리만도
아비르 엘-아이피
엠디 알 라힘
Original Assignee
더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리 오브 애그리컬쳐
더 유니버시티 오브 미시시피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리 오브 애그리컬쳐, 더 유니버시티 오브 미시시피 filed Critical 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리 오브 애그리컬쳐
Publication of KR20140107112A publication Critical patent/KR20140107112A/ko
Application granted granted Critical
Publication of KR101929074B1 publication Critical patent/KR101929074B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137032950A 2011-05-11 2012-05-10 프티로스틸벤의 항불안 효과 Expired - Fee Related KR101929074B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/105,470 US9439875B2 (en) 2011-05-11 2011-05-11 Anxiolytic effect of pterostilbene
US13/105,470 2011-05-11
PCT/US2012/037325 WO2012154956A2 (en) 2011-05-11 2012-05-10 Anxiolytic effect of pterostilbene

Publications (2)

Publication Number Publication Date
KR20140107112A KR20140107112A (ko) 2014-09-04
KR101929074B1 true KR101929074B1 (ko) 2018-12-13

Family

ID=47140003

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137032950A Expired - Fee Related KR101929074B1 (ko) 2011-05-11 2012-05-10 프티로스틸벤의 항불안 효과

Country Status (9)

Country Link
US (1) US9439875B2 (https=)
EP (1) EP2706992B1 (https=)
JP (2) JP6027607B2 (https=)
KR (1) KR101929074B1 (https=)
CN (1) CN103561729B (https=)
AU (1) AU2012253479B2 (https=)
BR (1) BR112013028776B1 (https=)
CA (1) CA2839309C (https=)
WO (1) WO2012154956A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
ES2649730T3 (es) 2013-03-15 2018-01-15 Glia Llc Distribución craneal de compuestos farmacéuticos
CN103333141B (zh) * 2013-06-05 2015-04-29 宁波大学 一种白藜芦醇低聚茋类化合物及其制备方法和应用
JP6406865B2 (ja) * 2014-04-25 2018-10-17 森永製菓株式会社 濃度測定方法
JP6463956B2 (ja) * 2014-11-28 2019-02-06 キユーピー株式会社 乳化組成物及びその製造方法
CN104706627A (zh) * 2015-03-12 2015-06-17 厦门大学 一种治疗缺血性脑中风的药物
WO2017011318A1 (en) 2015-07-10 2017-01-19 University Of Miami Methods for treating mucopolysaccharidosis
EP3500267A4 (en) 2016-08-22 2020-03-18 Elysium Health, Inc. NICOTINAMIDRIBOSIDE AND PTEROSTILLE COMPOSITIONS AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES
WO2018213715A1 (en) * 2017-05-18 2018-11-22 Elysium Health, Inc. Methods and compositions for improving sleep
JP6619108B2 (ja) * 2019-01-07 2019-12-11 キユーピー株式会社 乳化組成物及びその製造方法
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
CN110075094A (zh) * 2019-02-27 2019-08-02 延边大学 紫檀芪在制备药物或保健品中的应用
CN112618520A (zh) * 2021-01-14 2021-04-09 姚大纯 紫檀芪或白藜芦醇在制备用于治疗或改善孤独症谱系障碍的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010095943A2 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020999A2 (en) * 2004-08-19 2006-02-23 The United States Of America, As Represented By The Secretary Of Agriculture Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
US20060216331A1 (en) * 2005-02-28 2006-09-28 Lines Thomas C Composition for treating mental health disorders
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US20090163580A1 (en) * 2007-12-24 2009-06-25 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
JP5526762B2 (ja) * 2009-02-17 2014-06-18 Ｊｎｃ株式会社 誘電率異方性が負の液晶性化合物、これを用いた液晶組成物および液晶表示素子
US9737495B2 (en) * 2009-06-22 2017-08-22 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010095943A2 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning

Also Published As

Publication number Publication date
KR20140107112A (ko) 2014-09-04
CN103561729A (zh) 2014-02-05
EP2706992B1 (en) 2019-09-04
EP2706992A4 (en) 2014-12-17
HK1194302A1 (zh) 2014-10-17
WO2012154956A2 (en) 2012-11-15
WO2012154956A3 (en) 2013-01-24
US20160067192A1 (en) 2016-03-10
BR112013028776A2 (pt) 2017-01-24
CA2839309C (en) 2019-05-07
BR112013028776B1 (pt) 2022-04-19
EP2706992A2 (en) 2014-03-19
CA2839309A1 (en) 2012-11-15
US9439875B2 (en) 2016-09-13
JP6027607B2 (ja) 2016-11-16
AU2012253479A1 (en) 2013-11-28
JP2017014284A (ja) 2017-01-19
CN103561729B (zh) 2016-03-09
JP2014514361A (ja) 2014-06-19
AU2012253479B2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
KR101929074B1 (ko) 프티로스틸벤의 항불안 효과
US11529320B2 (en) Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
RU2563991C2 (ru) Синергические комбинации каротиноидов и полифенолов
Lu et al. Targeting oxidative stress and endothelial dysfunction using tanshinone IIA for the treatment of tissue inflammation and fibrosis
TW201033182A (en) Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
Nishikawa et al. Anti-inflammatory and anti-oxidative effect of curcumin in connective tissue type mast cell
WO2021077034A1 (en) 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders
You et al. More ulam for your brain: a review on the potential role of ulam in protecting against cognitive decline
KR101851010B1 (ko) 항염증 및 항균활성을 가지는 조성물
KR102793376B1 (ko) 호두 추출물을 포함하는 퇴행성 뇌신경 질환 예방 또는 치료용 조성물
EP2992879B1 (en) Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof
EP2957285B1 (en) Phospholipid compound containing unsaturated fatty acid derivative having cyclopropane ring
KR101855087B1 (ko) 칼콘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 미토콘드리아의 산소 소모율 감소에 의해 야기되는 질환의 예방 또는 치료용 약학 조성물
AU2014317857B2 (en) Regulation of body weight gain by using dibenzo-alpha-pyrones
HK1194302B (en) Use of pterostilbene for the manufacture of a pharmaceutical composition for the treatment, alleviation, or prevention of anxiety
KR100759467B1 (ko) 차가버섯 또는 상황버섯으로부터 분리된 화합물을 함유하는통풍 예방 및 치료용 조성물
KR20210113203A (ko) 대추나무 및 과라나에 있는 생물활성 식물화학물질
US12558348B2 (en) Bioactive phytochemicals
Qu Exploring the Anti-Alzheimer’s Disease Effects of Nano-Honokiol on TgCRND8 Transgenic Mice: Focusing on Gut Microbiota
Djehiche Study of anti-inflammatory and immunomodulatory properties of Ammodaucus leucotrichus
CN105997962B (zh) 辅酶q10在治疗周期性麻痹疾病中的应用
IL307326A (en) A new sulfonamide series of qr2 inhibitors to deal with oxidative stress and cognitive decline
CN118742304A (zh) 用于神经退行性疾病的化合物和组合物
HK40115347A (zh) 用於神经退行性疾病的化合物和组合物
JP2013189420A (ja) マクロジオライド化合物及びその用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20211124

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20221124

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241208

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241208

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241208